About AVIGI

An Unlikely
Hero.

Our journey began with the disaccharide — a small, unassuming sugar that turned out to hold the blueprint for a precision heparanase inhibitor.

Our background

We don't just think outside the box — we dissolve it, analyse it, and reassemble it into something extraordinary. Within the unassuming structure of a disaccharide we found the basis for a groundbreaking heparanase inhibitor.

Our focus

Heparanase sits at the crossroads of tissue remodelling, kidney disease and cancer. Inspired by nature's own molecules, we engineered a disaccharide-inspired inhibitor that selectively halts heparanase without disrupting healthy cellular processes — biomimicry, with a little scientific flair.

Timeline

A few public milestones

2025
UNIIQ boosts AVIGI
A first commitment from the regional development fund of South-Holland — a €350K convertible loan to accelerate development.
2024
Founding AVIGI Therapeutics
Incorporated under a bold new name — AVIGI Therapeutics B.V., headquartered in Leiden — and incubated at Unlock_.
2023
ERC & NWO PoC funding
The European Research Council and NWO awarded proof-of-concept funding. We took part in the Venture Challenge — then under the name Triangle Therapeutics.
2022
Discovery of our lead candidate
Composition-of-matter patent filed and key innovations published — including the structural mechanism deposited as PDB 7PR7.